The product is developed and manufactured by Indoco Remedies for TEVA at its facility in Goa.
The ANDA approved by the US Food and Drug Administration for Brinzolamide Ophthalmic
Suspension 1%, is used to treat high pressure inside the eye due to ocular hypertension and
open-angle glaucoma. Brinzolamide Ophthalmic Suspension 1% works by decreasing the
amount of fluid within the eye.
The US market size of this product is $184 million, according to IQVIA data as of December, 2020.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader,
Good news for reopening schools March 07 2021
COVID-19 cases and deaths continue trending down after Oregon Gov. Kate Brown issues an executive order to reopen public schools.
Newly reported COVID-19 cases and deaths continued trending down two days after Oregon Gov. Kate Brown issued an executive order to reopen public schools in coming weeks.
Brown mandated on Friday, March 5, that public school students be back in classrooms before the weeks of March 29 for elementary students and April 19 for middle and high schoolers. Whether or not public schools should return kids to the classroom this spring is no longer up for discussion: the science and data is clear, schools can return to in-person instruction with a very low risk of COVID-19 transmission, particularly with a vaccinated workforce, Brown said in a letter to state health and education agencies.
Capital Trust Ltd, Shree Rama Newsprint Ltd, Vivimed Labs Ltd and Inventure Growth & Securities Ltd are among the other gainers in the BSE s B group today, 09 March 2021.
Capital Trust Ltd, Shree Rama Newsprint Ltd, Vivimed Labs Ltd and Inventure Growth & Securities Ltd are among the other gainers in the BSE s B group today, 09 March 2021.
Aurionpro Solutions Ltd soared 20.00% to Rs 100.5 at 11:56 IST. The stock was the biggest gainer in the BSE s B group. On the BSE, 92284 shares were traded on the counter so far as against the average daily volumes of 5805 shares in the past one month.
Capital Trust Ltd surged 20.00% to Rs 117.6. The stock was the second biggest gainer in B group. On the BSE, 14968 shares were traded on the counter so far as against the average daily volumes of 7177 shares in the past one month.
Exclusive content, features, opinions and comment - hand-picked by our editors, just for you.
Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
Track the industry of your choice with a daily newsletter specific to that industry.
Stay on top of your investments. Track stock prices in your portfolio.
NOTE :
This product is a monthly auto renewal product.
Cancellation Policy: You can cancel any time in the future without assigning any reasons, but 48 hours prior to your card being charged for renewal. We do not offer any refunds.
To cancel, communicate from your registered email id and send the mail with the request to assist@bsmail.in. Include your contact number for easy reference. Requests mailed to any other ID will not be acknowledged or actioned upon.
Vivimed Labs rose 3.76% to Rs 17.95 after the company announced that it received approval for two products from Uzbekistan Government.The company received approval for Bilastin tablets and Orzole combi. Both the products are manufactured at the company s Hyderabad-based facility that has been approved by PICS & Health Canada.
Bilastin tablets (brand name Flustin) is a second-generation antihistamine used in treating allergic Rhino conjunctivitis and Urticaria (hives).
Orzole combi (Ofloxacin + Ornidazole) is used in treating bacterial and parasitic infections. It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections.
Ramesh Krishnamurthy, CEO of Vivimed Labs said: We are very excited to receive approval to Vivimed s own products. Vivimed strategy is to increase its share of Branded products in CIS Markets. Vivimed shall be launching these products in 2021. Our purpose is to offer inno